Six questions for the Trust's Chief Executive before the December Board
What the 17 November update says
The update was sent to pathology colleagues at both Trusts by Simon Tapley, the Trust's Chief Strategy and Planning Officer, and Chris Tidman, Deputy Chief Executive of the RD&E. It covers the following points.
- Cellular pathology. Work has continued on the business case to move routine cellular pathology to Gadeon House. An update on the full business case is due at the Trust's Board in December 2026, recommending a collaborative option with the RD&E. Subject to Board approval, the Trusts would then develop the business case for an integrated Torbay and RD&E cellular pathology service at Gadeon House.
- The reasons given. The current laboratory is described as a life-expired temporary building. The update says the move would also reduce pressure on constrained clinical space at Torbay Hospital and support the longer-term development of the site.
- Microbiology and blood sciences. The Trusts had intended to take a full business case for wider collaboration to their Boards this autumn. Having listened to feedback from clinical colleagues, they say they are not in a position to make recommendations. Proposals for wider collaboration will not go to the Boards as part of the current process. The Trusts will take more time to decide whether any future proposals should be developed, learn from the RD&E's own move, and return to the Boards at a later date if appropriate.
- The RD&E's own programme. The RD&E's Board approved its full business case in January 2026. Its non-urgent microbiology and blood sciences services are due to move to Gadeon House in autumn 2027, with urgent and time-critical testing kept in smaller laboratories at its Exeter and Barnstaple hospitals.
- Consultation. The update promises formal consultation with affected staff, which at the Trust will be subject to approval of the business case. It does not mention consultation with patients or the public.
- Patients. The update says there will be no changes to where patients receive care because of these moves.
- The wider picture. Both Trusts remain part of the Peninsula Pathology Network, which is developing a regional Target Operating Model for pathology.
What the campaign has asked
Susie Colley, Chair of Save Torbay Hospital, says the update leaves the Trust pressing ahead with routine cellular pathology alone, while it has not yet assessed what happens to the services left at Torbay or to the staff affected. She asks the Chief Executive to set out, before the December Board:
- The total capital and revenue the Trust expects to commit to the histopathology relocation, including any lease, fit-out or service charge at Gadeon House, and over what term.
- How that spend represents value for money if no other pathology specialty moves.
- What assessment has been made of the impact on the services that will stay at Torbay, including urgent histopathology and support to the DGH.
- What workforce impact assessment has been done, and how many posts are affected.
- Why reinvesting in an on-site facility at Torbay was rejected, and where that options appraisal can be seen.
- Whether the Board will see a full, published business case before it takes any decision.
From: Susie Colley, Director, Save Torbay Hospital Ltd, and Chair of Save Torbay Hospital
To: Joe Teape, Chief Executive, Torbay and South Devon NHS Foundation Trust
Copied to: Danny Beales MP, Beccy Cooper MP, Josh Fenton-Glynn MP, Paulette Hamilton MP, Joe Robertson MP and Greg Stafford MP (members of the Health and Social Care Committee), and the campaign's legal advisers
Subject: Pathology update of 17 November, what exactly is Torbay paying for?
Good evening Mr Teape,
I have read the pathology update issued today by Simon Tapley and Chris Tidman, and frankly it raises more questions than it answers.
The update confirms that the wider collaboration on microbiology and blood sciences has been shelved. That leaves the Trust pressing ahead with one thing only: moving routine (elective) histopathology to Gadeon House. Yet the Trust is still preparing to commit very substantial funds to that move.
How can that level of spend possibly be justified for elective histopathology alone?
A move like this only makes financial or operational sense if every pathology specialty follows. By your own colleagues' admission, that work has not been done. The update says further work is needed to "fully understand the operational, workforce and logistical implications". Nobody has assessed what happens to the services left behind at Torbay: urgent cellular pathology, frozen sections, support for cancer pathways and the wider DGH, or the staff who will be split between two sites or lost altogether.
You are, in effect, asking the Board in December to approve the first piece of a jigsaw while admitting you don't yet know what the finished picture looks like. That is not strategy. It is drift.
The update also makes clear where the direction is coming from. Royal Devon's programme is approved, funded and under way, and Torbay is invited to "learn from" it. The Peninsula Pathology Network is cited as the wider context. Torbay is not leading this. We are following RDUH and the ICB, and the network label does not change that.
I would therefore ask you to set out, before the December Board:
- The total capital and revenue the Trust expects to commit to the histopathology relocation, including any lease, fit-out or service charge at Gadeon House, and over what term.
- How that spend represents value for money if no other pathology specialty moves.
- What assessment has been made of the impact on the services that will stay at Torbay, including urgent histopathology and support to the DGH.
- What workforce impact assessment has been done, and how many posts are affected.
- Why reinvesting in an on-site facility at Torbay was rejected, and where that options appraisal can be seen.
- Whether the Board will see a full, published business case before it takes any decision.
The update says there will be "no changes to where patients receive care". For patients whose diagnosis and treatment depend on pathology done on site, the Trust has not shown that this is true.
The people of Torbay and South Devon deserve answers before money is committed, not after. I look forward to your reply.
Thank you.
Kindest regards
Susie Colley
Director, Save Torbay Hospital Ltd
What happens next
There is no statutory deadline for the Chief Executive to reply to a letter. The letter asks for answers before the Trust's December Board meeting, where the cellular pathology business case is due to be considered. This item will be updated when the Trust replies, and when the Board papers for December are published.
